CDKN3 and cancer: The 5-fluorouracil signature included genes for transcription regulation and a cyclin-dependent kinase inhibitor (CDKN2A) thought to play a role in cancer progression, while the cyclophosphamide signature included genes (e.g. SET) commonly involved in leukemogenesis.